Advanced Filters
noise

Tokyo and Other Japanese City, Japan Clinical Trials

A listing of Tokyo and Other Japanese City, Japan clinical trials actively recruiting patients volunteers.

Found 65,447 clinical trials
E Erin Loweree

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery

To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.

22 - 100 years of age All Phase 4
K Kenneth Watanabe, Clinical Research Coordinator

Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

The COSMID (Comparison of Surgery and Medicine on the Impact of Diverticulitis) trial is a pragmatic, patient-level randomized superiority trial of elective colectomy vs. best medical management for patients with quality of life (QoL) limiting diverticular disease. A parallel observational cohort will include those who are disinclined to have their …

18 years of age All Phase N/A

Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial

A multi-center, prospective, randomized, open-label, adaptive group sequential designed, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS

18 years of age All Phase N/A
J Juha KA Rinne, MD

Day Case Colectomy: Optimizing Short Stay-surgery.

HRV measurement of patients recovering from laparoscopic colorectal resection for any pathology.

18 - 100 years of age All Phase N/A
C Carolin Steinack, MD

Noninvasive Early Detection of Lung Allograft Dysfunction After Lung Transplantation With Multiple Breath Washout Test

Chronic rejection, more commonly called bronchiolitis obliterans syndrome (BOS), is the leading cause of death beyond the first year post lung transplantation. The diagnosis of BOS is typically made by clinical, physiological, and radiographic parameters. Early detection would be desirable since it allows treatment modification to stop or delay the …

18 years of age All Phase N/A

Integrated Treatment in FND (Functional Neurological Disorders)

The project will investigate the effectiveness of patient-centered integrated treatment. The correlations between physiotherapy indices, non-invasive brain stimulation, connectivity and psychological support will be analyzed.

18 - 65 years of age All Phase N/A
Z Zijiang He, Ph.D.

Intermediate Visual Space Perception

The ability to judge the locations of various objects from oneself during self-motion in the intermediate distance range (~2-25m) is crucial for successful performance of activities of daily living, such as walking and driving. However, little is known about the mechanisms of visual space perception involved in judging distance, the …

18 - 40 years of age All Phase N/A
T Tina Greenlee

SMART Embedded Intervention for Military Postsurgical Engagement Readiness

The overarching objective of this proposal is to conduct a multi-site Sequential Multiple Assignment Randomized Trial (SMART) across multiple Military Health System (MHS) sites to optimize the sequencing and integration of two intervention strategies in total knee arthoplasty (TKA) patients: a single-session mindfulness-based intervention (MBI) and an intensive 8-week MBI-Mindfulness-Oriented …

18 years of age All Phase N/A
E Elias Jabbour, MD

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may …

18 years of age All Phase 2
Y Ying Lin, MD

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.

18 - 75 years of age All Phase 2

Simplify language using AI